On September 12, 2024, the Food and Drug Administration sanctioned atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous administration for all adult indications co...
subcutaneous-immunotherapy
Nov 2023: Elranatamab-bcmm (Elrexfio, Pfizer, Inc.) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager that was given accelerated approval by the Food and Drug Administratio...
subcutaneous-immunotherapy
July 2023: The Food and Drug Administration gave accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise spec...
subcutaneous-immunotherapy